Regulators Insist On Large-Scale Trials For Coronavirus Treatment Candidates
Regulators Also Highlight Need To Preserve Supplies For Non-COVID-19 Uses
Executive Summary
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.